MARKET OVERVIEW
The global gastric cancer drugs market reached USD 5.2 Billion in 2024 and is projected to hit USD 13.5 Billion by 2033, growing at a CAGR of 10.7% during 2025-2033. This expansion is primarily driven by the rising geriatric population and increasing obesity prevalence, both of which heighten gastric cancer risks. Advancements in oncology treatments and growing healthcare awareness are further stimulating the gastric cancer drugs market.
STUDY ASSUMPTION YEARS
- Base Year: 2024
- Historical Years: 2019-2024
- Forecast Years: 2025-2033
GASTRIC CANCER DRUGS MARKET KEY TAKEAWAYS
- The global gastric cancer drugs market stood at USD 5.2 Billion in 2024 and is projected to reach USD 13.5 Billion by 2033, reflecting a CAGR of 10.7%.
- North America accounted for the largest market share in 2024, supported by robust healthcare infrastructure, advanced drug pipelines, and early adoption of innovative therapies.
- Asia Pacific is anticipated to witness rapid growth, fueled by a large patient pool, increasing healthcare investments, and rising awareness about gastric cancer treatments.
- Growing geriatric population and obesity prevalence remain critical demographic drivers, boosting the demand for effective gastric cancer therapies.
- Advancements in targeted therapies, immuno-oncology, and biosimilars are shaping treatment options, enhancing survival rates, and offering lucrative growth opportunities.
Request for a sample copy of this report : https://www.imarcgroup.com/gastric-cancer-drugs-market/requestsample
MARKET GROWTH FACTORS
1. Expanding Geriatric Population and Rising Obesity Levels
The global surge in the elderly population has significantly increased the prevalence of gastric cancer, as age remains a critical risk factor. Older individuals often require specialized and tolerable treatment options, which is fueling demand for advanced drugs. Additionally, the growing incidence of obesity, a known contributor to gastric cancer development, is further amplifying the market need for effective therapies. These combined demographic factors provide a strong foundation for long-term market expansion, reinforcing the demand for next-generation cancer treatments.
2. Technological Advancements in Targeted and Immuno-Oncology Therapies
Ongoing technological progress in oncology has led to the emergence of innovative gastric cancer treatment approaches, including targeted therapies, biosimilars, and immuno-oncology agents. Drugs like trastuzumab and other HER2-targeted therapies are transforming patient care by improving survival outcomes and reducing side effects compared to traditional chemotherapy. In parallel, immunotherapies are rapidly gaining acceptance as frontline treatments. These advancements not only enhance treatment precision but also accelerate R&D pipelines, creating new opportunities for pharmaceutical companies and strengthening overall market growth.
3. Regulatory Approvals and Increased R&D Investments
Favorable regulatory environments and strong investment flows in research and development are bolstering the gastric cancer drugs market. Expedited approval pathways for breakthrough therapies and government initiatives aimed at supporting oncology research are enabling faster commercialization of novel treatments. Pharmaceutical companies are also increasingly collaborating with research institutions to expand their product pipelines. These supportive policies and rising investments are improving drug accessibility, stimulating competition, and ensuring patients benefit from faster, more effective, and affordable treatment innovations.
MARKET SEGMENTATION
Segmentation by Type
- Imatinib – A tyrosine kinase inhibitor widely used in targeted therapy, helping control cancer progression by blocking specific cellular pathways.
- Trastuzumab – A HER2-targeted monoclonal antibody, extensively used in treating HER2-positive gastric cancer patients.
- Other Types – Includes chemotherapy agents, targeted therapy agents, immunotherapy agents, and supportive care medications for comprehensive gastric cancer management.
Segmentation by Route of Administration
- Oral – Convenient oral formulations for patient self-administration, ensuring ease of treatment compliance.
- Parenteral – Injectable and infusion-based drug delivery for higher efficacy in advanced cancer treatment.
Segmentation by End User
- Hospitals – Primary centers for diagnosis, treatment, and administration of advanced gastric cancer drugs.
- Clinics – Outpatient facilities offering gastric cancer therapies and follow-up treatments.
- Cancer Specialty Centers – Dedicated oncology institutions focused on specialized gastric cancer treatment and drug administration.
Sub-Segmentation of Imatinib, by Type
- Oral Formulations
- Injectable Formulations
- Combination Therapies
Sub-Segmentation of Trastuzumab, by Type
- Monotherapy
- Combination Therapy with Chemotherapy
- Biosimilars of Trastuzumab
Sub-Segmentation of Other Types, by Type
- Chemotherapy Agents
- Targeted Therapy Agents
- Immunotherapy Agents
- Supportive Care Medications
Breakup by Region
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
REGIONAL INSIGHTS
North America dominated the gastric cancer drugs market in 2024, owing to its advanced healthcare infrastructure, strong drug development pipeline, and early adoption of innovative therapies. Supportive regulatory policies and high cancer awareness further reinforce the region’s leading position.
RECENT DEVELOPMENTS & NEWS
The gastric cancer drugs market is witnessing notable developments, with pharmaceutical companies focusing on expanding their oncology portfolios. Significant emphasis is being placed on biosimilars, targeted therapies, and immuno-oncology innovations. Strategic collaborations between biopharmaceutical firms and research institutes are accelerating clinical trials and expediting drug approvals. These trends highlight the market’s dynamic nature, with an increasing focus on personalized treatment approaches and improved survival outcomes for gastric cancer patients.
KEY PLAYERS
- Abbott Laboratories
- Arog Pharamaceuticals Inc.
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Ono Pharmaceutical Co. Ltd.
- Sanofi S.A.
- Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Ask Analyst for Customization:https://www.imarcgroup.com/request?type=report&id=6648&flag=C
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
